Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVAT-121 (cannabidiol)
- Development stage
- Phase 1
- Lead developer
- Sapience Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AVAT-121 (formerly SAP-021, and also referred to as AVAT-021) is an orally administered, solid-dose capsule formulation of synthetic, pharmaceutical-grade cannabidiol (CBD) being developed by Avata Biosciences (formerly Sapient Therapeutics). Utilizing Avata's proprietary water-soluble cannabinoid formulation technology, AVAT-121 is designed to improve the bioavailability and scalability of CBD compared to existing oil-based formulations like Epidiolex. The drug is currently in Phase 1 clinical development for the treatment of adult focal epilepsy and schizophrenia, the latter in partnership with the University of Oxford. AVAT-121 acts as a multimodal modulator of the endocannabinoid system and other neurological pathways, targeting cannabinoid receptors (CB1 and CB2), GPR55, TRPV1, and ENT1 to reduce neuronal hyperexcitability and neuroinflammation.
- Other names
- CBDsynthetic cannabidiol
02
Targets
CNR1 (Cannabinoid receptor 1)GPR55 (G protein-coupled receptor 55)ENT1 (Solute carrier family 29 member 1)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on AVAT-121 (cannabidiol).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVAT-121 (cannabidiol).